Allred DC - Search Results

1

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: allred dc. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

2

Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. McGuire WL, et al. Among authors: allred dc. Cancer. 1992 Sep 15;70(6 Suppl):1775-81. doi: 10.1002/1097-0142(19920915)70:4+<1775::aid-cncr2820701619>3.0.co;2-8. Cancer. 1992. PMID: 1355403

3

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Allred DC, et al. Hum Pathol. 1992 Sep;23(9):974-9. doi: 10.1016/0046-8177(92)90257-4. Hum Pathol. 1992. PMID: 1355464

4

Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.

Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL. Molina R, et al. Among authors: allred dc. Anticancer Res. 1992 Nov-Dec;12(6B):1965-71. Anticancer Res. 1992. PMID: 1363511

5

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al. Allred DC, et al. J Clin Oncol. 1992 Apr;10(4):599-605. doi: 10.1200/JCO.1992.10.4.599. J Clin Oncol. 1992. PMID: 1548522 Clinical Trial.

6

Improved methods of estimating mitotic activity in solid tumors.

Hilsenbeck SG, Allred DC. Hilsenbeck SG, et al. Among authors: allred dc. Hum Pathol. 1992 Jun;23(6):601-2. doi: 10.1016/0046-8177(92)90312-q. Hum Pathol. 1992. PMID: 1592380 No abstract available.

7

Treatment decisions in axillary node-negative breast cancer patients.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. McGuire WL, et al. Among authors: allred dc. J Natl Cancer Inst Monogr. 1992;(11):173-80. J Natl Cancer Inst Monogr. 1992. PMID: 1627425 Clinical Trial.

8

Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors.

Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL. Fuqua SA, et al. Among authors: allred dc. Cancer Res. 1992 Jan 15;52(2):483-6. Cancer Res. 1992. PMID: 1728420

9

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Osborne CK, et al. Among authors: allred dc. J Natl Cancer Inst. 1991 Oct 16;83(20):1477-82. doi: 10.1093/jnci/83.20.1477. J Natl Cancer Inst. 1991. PMID: 1920493

10

How to use prognostic factors in axillary node-negative breast cancer patients.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. McGuire WL, et al. Among authors: allred dc. J Natl Cancer Inst. 1990 Jun 20;82(12):1006-15. doi: 10.1093/jnci/82.12.1006. J Natl Cancer Inst. 1990. PMID: 2189998 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters